C4 Therapeutics
(NASDAQ) CCCC
C4 Therapeutics Financials at a Glance
Market Cap
$486.49M
Revenue (TTM)
$34.86M
Net Income (TTM)
-$103.80M
EPS (TTM)
-$1.18
P/E Ratio
-3.71
Dividend
$0.00
Beta (Volatility)
1.98 (High)
Dividend
$0.00
Beta (Volatility)
1.98 (High)
Price
$4.25
Volume
346,646
Open
$4.40
Price
$4.25
Volume
346,646
Open
$4.40
Previous Close
$4.25
Daily Range
$4.15 - $4.58
52-Week Range
$1.40 - $4.60
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.98 (High)
Price
$4.25
Volume
346,646
Open
$4.40
Previous Close
$4.25
Daily Range
$4.15 - $4.58
52-Week Range
$1.40 - $4.60
Estimated Earnings Date
Aug 6, 2026
CCCC News
CCCC: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout C4 Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
104
CEO
Andrew J. Hirsch, MBA
Website
www.c4therapeutics.comHeadquarters
Watertown, MA 02472, US
CCCC Financials
Key Financial Metrics (TTM)
Gross Margin
94.83%
Operating Margin
-326.56%
Net Income Margin
-297.76%
Return on Equity
-50.68%
Return on Capital
-33.01%
Return on Assets
-31.56%
Earnings Yield
-26.95%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$486.49M
Shares Outstanding
110.57M
Volume
346.65K
Avg. Volume
2.81M
Financials (TTM)
Gross Profit
$33.06M
Operating Income
-$113.84M
EBITDA
-$100.38M
Operating Cash Flow
-$95.35M
Capital Expenditure
-$671.00K
Free Cash Flow
-$96.02M
Cash & ST Invst.
$235.67M
Total Debt
$58.45M
C4 Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$6.15M
-15.0%
Gross Profit
$4.35M
-39.9%
Gross Margin
70.72%
N/A
Market Cap
$486.49M
N/A
Market Cap/Employee
$4.42M
N/A
Employees
110
N/A
Net Income
-$25.13M
+4.5%
EBITDA
-$23.33M
+9.8%
Quarterly Fundamentals
Total Cash
$235.67M
+9.6%
Total Debt
$58.45M
-9.2%
Accounts Receivable
$2.88M
-64.1%
Inventory
$0.00
N/A
Long Term Debt
$51.93M
-11.2%
Short Term Debt
$6.52M
+10.2%
Return on Assets
-31.56%
N/A
Return on Invested Capital
-37.74%
N/A
Free Cash Flow
-$30.01M
+9.8%
Operating Cash Flow
-$29.94M
+10.0%